RHOT1 and Parkinson disease: PD patients carrying PINK1 and PRKN mutations (see Table S1, Figs. S2 and S3) had unchanged Miro1 levels from baseline for the first 4 hours of CCCP treatment and then an increase to ~1.2 ( + CCCP/DMSO) (Fig. 2A).